Adrabetadex

Adrabetadex (HPBCD, formerly VTS-270) is a 2-hydroxypropyl-beta-cyclodextrin under FDA review for infantile-onset Niemann-Pick Disease Type C (I-NPC), a rapidly fatal pediatric lysosomal storage disease in which cholesterol piles up inside cells and progressively kills neurons in infancy and early childhood [1]. The asset has a long corporate lineage: Sucampo and then Mallinckrodt ran the original program (intrathecal VTS-270), which missed its Phase 2/3 primary composite endpoint in 2019 and was discontinued [5]. Mandos LLC, now a subsidiary of Beren Therapeutics, acquired the asset from Mallinckrodt and refiled on the infantile subset. Beren submitted the NDA in December 2025; FDA accepted it with Priority Review (an FDA designation that shortens target review time to 6 months for drugs offering meaningful improvement over existing therapies) in February 2026 [9]. The original PDUFA target action date of August 17, 2026 was extended by three months to November 17, 2026 after FDA classified Beren's March 18, 2026 response to an FDA information request as a Major Amendment [10]. Major Amendments often precede Complete Response Letters and signal that FDA had substantive post-submission questions. A separate Cyclo Therapeutics Phase 3 of the same active ingredient via IV dosing (NCT04860960) is active and not recruiting in a broader NPC1 population [2], distinct from Beren's I-NPC indication. The competitive backdrop tightened in September 2024 when FDA approved arimoclomol (Miplyffa) and levacetylleucine (Aqneursa) for NPC [6][7]. Miglustat (Zavesca) has been EU-approved for NPC since 2009 and is widely used off-label in the US [8], so adrabetadex would enter a market that already has standard-of-care options.

NDA accepted February 2026 with Priority Review, Orphan Drug Designation (both US and EU, granted in the Sucampo/Mallinckrodt era), and Breakthrough Therapy Designation (an FDA status accelerating development of drugs that show early signal of substantial improvement over existing therapies for serious conditions) [5][9]. PDUFA target action date November 17, 2026 [10]. The molecule itself, 2-hydroxypropyl-beta-cyclodextrin, has been used for decades as a pharmaceutical excipient (a solubilizer that helps water-insoluble drugs dissolve), so its low-dose safety pharmacology is well-characterized. The therapeutic application at higher CNS-targeting doses is the novel aspect, not the chemical entity itself. Beren's NDA filing for infantile-onset NPC is supported primarily by long-term follow-up of patients from the original intrathecal program (NCT02534844) compared to matched external controls, with Beren reporting a 71% reduction in mortality risk in adrabetadex-treated I-NPC patients versus matched external controls [9]. The parallel Phase 3 (NCT04860960) sponsored by Cyclo Therapeutics, with their Trappsol Cyclo IV HPBCD product, is active not recruiting, n=94, primary endpoint change from baseline in the 4-Domain NPC Severity Score [2]. This is a separate clinical program with a different sponsor, IV (rather than intrathecal) administration, and a broader NPC1 patient population, but uses essentially the same active ingredient. Two HPBCD programs in different patient subsets and different routes may explain why both can coexist, but FDA will likely evaluate the I-NPC submission with reference to the broader cyclodextrin safety database.

NPC (the disease) is caused by mutations in the NPC1 gene, which makes a protein that normally acts like a forklift, moving cholesterol out of lysosomes. Lysosomes are the cellular recycling centers where worn-out parts get broken down. When NPC1 does not work properly, cholesterol piles up inside lysosomes, mostly in brain cells. Over years, neurons get sick and die. In the infantile-onset subset (I-NPC) targeted by Beren's NDA, disease progression is markedly faster than juvenile or adult-onset forms, with severe liver involvement, profound neurodegeneration, and death typically before age 5. Children develop progressive ataxia (loss of coordination), seizures, dementia, and most die before adulthood. Cyclodextrins are donut-shaped sugar molecules with a hollow core, and the core happens to be the right size and shape to grab a cholesterol molecule and pull it out. The therapeutic idea: get HPBCD into cells, where it finds cholesterol stuck in lysosomes and shuttles it out so the cell can process it through normal pathways. The mechanism is validated in NPC mouse and cat models with substantial life extension when dosing starts early. Two problems complicate the clean story. First, getting cyclodextrin into the brain at therapeutic concentrations is hard, which is why Beren's program used intrathecal (spinal fluid) injection. IV dosing in the Cyclo Therapeutics program is more convenient for patients but raises questions about CNS exposure. Second, ototoxicity (hearing damage) shows up at therapeutic doses in animals and in patients, because cyclodextrin pulls cholesterol out of inner-ear hair cells too [12]. The dose-response window is narrow.

Beren's NDA for I-NPC is supported chiefly by long-term follow-up of the Mandos/Mallinckrodt Phase 2/3 (NCT02534844, intrathecal, n=56), reanalyzed for the infantile subset and compared to matched external controls [3][9]. The overall composite NPC Severity Score primary endpoint of the original trial was not statistically significant compared to historical controls in 2019 [3][5]. Beren's filing strategy pivots to a mortality endpoint in the infantile subset, with reported 71% reduction in mortality risk versus matched external controls [9]. The choice of external controls, rather than a contemporaneous placebo arm, is a known weakness for slow-progressing diseases, though it is more defensible for an ultra-rare rapidly fatal pediatric population where placebo-controlled mortality trials are ethically difficult. The Major Amendment classification of Beren's March 2026 response to an FDA information request suggests FDA had substantive questions about the external-control matching, the survival analysis, or the I-NPC subset definition [10]. The separate Cyclo Therapeutics Phase 3 (NCT04860960) enrolls a broader pediatric and adult NPC1 population, n=94, active not recruiting, primary endpoint change from baseline in the 4-Domain NPC Severity Score, placebo-controlled [2]. The NPC Severity Score is validated and shows high inter-rater reliability per Farhat 2022 [1], but at n=94 spread across a heterogeneous adult and pediatric population, powering on a composite that progresses on a multi-year timescale is statistically tight. Earlier infantile liver disease work at Washington University (NCT03471143, n=4, completed) tested a biomarker endpoint, not a clinical outcome [4]. Concomitant miglustat (background standard-of-care) was permitted in both programs, which makes interpretation of placebo-arm progression dependent on how many patients were on it and for how long [8].

This drug is under FDA review (NDA/BLA), with a PDUFA decision date of 2026-08-17. Our estimate of 93% is the historical filing-approval rate for its area, adjusted for its rejection history (no prior Complete Response Letters). At this stage the early-trial design model no longer applies - what matters is that it reached the FDA and whether it has been rejected before.

Efficacy: the original intrathecal program missed its primary composite endpoint in 2019 [3][5]. Beren's I-NPC mortality reframing is a post-hoc subset analysis, which FDA discounts. Cross-trial extrapolation between Beren's intrathecal program and the Cyclo Therapeutics IV trial is weak (different route, different dose, different sponsor, different population), but the directional read on the active ingredient is hard to ignore. Safety: cyclodextrin-induced ototoxicity is mechanism-based and dose-dependent. Hearing loss was documented in animal models and in patients on the intrathecal program [12]. Audiology monitoring is required throughout treatment. The IV route exposes systemic tissues to higher cyclodextrin concentrations to achieve CNS delivery, which sustains the ototoxicity question. Regulatory: the May 2026 Major Amendment classification and 3-month PDUFA extension to November 17, 2026 indicates FDA had substantive post-submission questions [10]. Major Amendments historically precede Complete Response Letters at higher than baseline rates. The specific issues FDA raised have not been disclosed but most likely concern external-control matching, survival analysis methodology, or the I-NPC subset definition. Commercial: the NPC market is small (roughly 1 in 100,000 births), and the I-NPC subset is a fraction of that. Pricing for ultra-rare lysosomal storage drugs typically runs $300K-$700K per year. The competitive picture is more crowded than it looks. Miglustat (Zavesca) is EU-approved (2009) for NPC and used off-label in the US as background substrate reduction therapy; it works by inhibiting glucosylceramide synthase to reduce glycosphingolipid buildup, mechanistically distinct from cyclodextrin's cholesterol-trafficking approach [8]. Miplyffa (arimoclomol) and Aqneursa (levacetylleucine) were approved September 2024 [6][7]. Adrabetadex would enter as the fourth NPC option, though the only one targeting I-NPC specifically on a survival endpoint. Payer pushback on cost-effectiveness against existing standard of care is a real possibility.

Worth watching, with low expected value. The PDUFA target action date is November 17, 2026, not the August date previously circulated [10]. The 3-month extension and Major Amendment classification is the most material recent signal: FDA had substantive post-submission questions, and Major Amendments correlate with elevated Complete Response Letter rates. The cleaner independent data point is the Cyclo Therapeutics Phase 3 (NCT04860960) primary readout, which has not yet been disclosed publicly [2]. The bull case is approval (possibly with REMS or post-marketing study attached) on the I-NPC mortality endpoint, with differentiated positioning from Miplyffa, Aqneursa, and background miglustat as the only therapy specifically labeled for the infantile-onset subset. The bear case is a Complete Response Letter requesting additional confirmatory data, replaying the 2019 endpoint-miss pattern in a new regulatory wrapper [5]. The base case is regulatory action by November 17, 2026 with the read more likely negative than positive given prior signal, the Major Amendment flag, and the new competitive context. Check back when an FDA AdComm date posts for Q3 2026, when the Cyclo Therapeutics Phase 3 topline drops, or on the PDUFA date itself.